Clinical Scorecard: Fungemia Caused by Kazachstania slooffiae: A Case Study and Review of Literature on an Emerging Opportunistic Fungal Pathogen in Humans
At a Glance
Category
Detail
Condition
Kazachstania slooffiae fungemia, an emerging opportunistic fungal bloodstream infection
Key Mechanisms
Opportunistic infection in immunocompromised hosts with gastrointestinal abnormalities; diagnosis via MALDI-TOF MS and DNA sequencing
Target Population
Critically ill, immunocompromised patients with GI anatomic abnormalities, underlying malignancy, or chronic illness
Care Setting
Medical intensive care unit and specialized infectious disease care settings
Key Highlights
First documented case of Kazachstania slooffiae fungemia in a human, expanding known pathogenicity beyond nonbloodstream infections
Diagnosis requires advanced laboratory methods including MALDI-TOF mass spectrometry and DNA sequencing due to difficulty in speciation
Antifungal therapy with echinocandins (micafungin, caspofungin) and fluconazole has resulted in favorable clinical outcomes
Guideline-Based Recommendations
Diagnosis
Use matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for yeast identification when conventional methods fail
Confirm identification with DNA sequencing for accurate species-level diagnosis
Management
Initiate empiric antifungal therapy with echinocandins (e.g., micafungin) for fungemia based on Infectious Diseases Society of America candidemia guidelines
Continue antifungal treatment for extended duration (e.g., 6 weeks) if endocarditis or deep-seated infection is suspected
Consider source control measures such as drainage of pleural effusions or gastric decompression
Monitoring & Follow-up
Repeat blood cultures after antifungal initiation to confirm clearance of fungemia
Perform echocardiographic evaluation to assess for endocarditis, adapting approach based on patient anatomy
Monitor clinical signs of infection resolution and organ function
Risks
Immunocompromised status and gastrointestinal anatomic abnormalities increase risk of invasive Kazachstania slooffiae infection
Delayed or inaccurate identification may lead to inappropriate management
Potential for co-infections with bacterial pathogens complicating clinical course
Patient & Prescribing Data
Immunocompromised adults with gastrointestinal abnormalities and critical illness
Echinocandin antifungals such as micafungin are effective first-line agents; fluconazole and caspofungin have also been used successfully; MIC testing may not always be available
Clinical Best Practices
Maintain high suspicion for rare fungal pathogens in immunocompromised patients with sepsis and GI abnormalities
Utilize advanced diagnostic modalities early to ensure accurate pathogen identification
Implement prompt antifungal therapy guided by candidemia treatment guidelines
Ensure thorough source control and supportive care in critically ill patients
Monitor treatment response with repeat cultures and imaging as indicated
Older age, male sex, underweight status, reduced activities of daily living, and mild consciousness disturbance were associated with postextubation pneumonia in elective surgical patients.
